Intrexon (XON) Earns News Impact Rating of 0.19

Media coverage about Intrexon (NYSE:XON) has been trending somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Intrexon earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.0305616409215 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media stories that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Several brokerages have issued reports on XON. ValuEngine lowered shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Northland Securities reiterated a “buy” rating and set a $17.00 target price on shares of Intrexon in a research report on Friday, March 2nd. Bank of America decreased their price target on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday, March 2nd. Zacks Investment Research raised shares of Intrexon from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, JPMorgan Chase reissued a “neutral” rating and set a $18.00 price target (down from $22.00) on shares of Intrexon in a research note on Monday, March 5th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Intrexon presently has a consensus rating of “Hold” and an average price target of $34.67.



XON stock opened at $19.62 on Friday. The company has a market cap of $2,564.54, a price-to-earnings ratio of -21.33 and a beta of 1.11. Intrexon has a one year low of $10.26 and a one year high of $26.99. The company has a current ratio of 1.92, a quick ratio of 1.67 and a debt-to-equity ratio of 0.01.

Intrexon (NYSE:XON) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. The firm had revenue of $77.03 million for the quarter, compared to the consensus estimate of $48.16 million. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The business’s revenue was up 67.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.37) earnings per share. analysts anticipate that Intrexon will post -0.92 EPS for the current year.

In other Intrexon news, CEO Randal J. Kirk purchased 1,000,000 shares of the firm’s stock in a transaction on Friday, January 19th. The shares were purchased at an average cost of $12.50 per share, with a total value of $12,500,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 55.10% of the company’s stock.

WARNING: This story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://stocknewstimes.com/2018/04/15/intrexon-xon-earns-news-impact-rating-of-0-19.html.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply